ArticleBMC cancer2026
A pilot study assessing the feasibility of contrast-enhanced ultrasound for triaging fine-needle aspiration in lateral cervical lymph nodes of papillary thyroid carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the role of contrast-enhanced ultrasound (CEUS) in preoperative ultrasound-guided fine-needle aspiration (US-FNA) of lateral cervical lymph nodes (LCLN) in patients with papillary thyroid carcinoma (PTC).
methodsA total of 112 patients with 164 suspicious LCLN were enrolled into two cohorts based on whether they received CEUS examination before US-FNA. In the conventional cohort, 64 nodules from 42 patients underwent direct US-FNA, while in the CEUS-triage cohort, 100 nodules from 70 patients performed CEUS examination first. Among these, 28 homogeneously-centrifugal enhanced nodules were exempt from FNA, and 72 nodules proceeded to US-FNA. The effectiveness of FNA and the cumulative recurrence rate (CRR) during the follow-up period were compared between the two cohorts. The CEUS characteristics of metastatic LCLN were also summarized.
resultsThere was a significant difference in the rate of US-FNA performed between the CEUS-triage cohort and the conventional cohort (72.0% vs. 100.0%, p < 0.001). The CEUS-triage cohort had a lower uncertainty rate of FNA (6.9% vs. 18.8%, p = 0.04). All patients were followed up for an average of 38.4 months. There was no significant difference in the CRR between the two groups in the entire cohort and the surgical population (all p > 0.05). CEUS of metastatic LCLN in PTC showed centripetal enhancement, hypo-enhancement, heterogeneous enhancement, and perfusion defects (all p < 0.001).
conclusionsCEUS may have the potential to serve as a valuable triage tool for US-FNA of suspicious LCLN in PTC patients, potentially reducing unnecessary puncture rates and increasing the overall diagnostic yield of biopsies. Features such as centripetal enhancement, hypo-enhancement, heterogeneous enhancement, and perfusion defects observed on CEUS were more frequently linked to metastatic lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.